PDCD1 and melanoma: Correspondingly, there are several clinically available PD1/PD-L1 inhibitors approved by FDA for cancer treatment ranging from melanoma to NSCLC, including but not restricted to pembrolizumab, nivolumab, atezolizumab, and avelumab.